Internal Medicine, Hematology & Oncology · La Mesa, CA
NPI
1154618593
Since 2011
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
5555 Grossmont Center Dr
La Mesa, CA, 91942
Phone (619) 644-3030
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.2M
251,351 services
Medicare patients, 2024
500
Average age 74
Drug cost, 2024
$6.7M
1,612 prescriptions
Company payments, 2025
$3,052
From 47 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Igor Medic was code J1439 (injection, ferric carboxymaltose, 1 mg), 63,750 times for 37 patients. In total Igor Medic billed 251,351 services in 113 codes, and Medicare paid $4.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 63,750 | 37 | $0.87 | $55K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 42,300 | 22 | $2.33 | $99K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 29,600 | 19 | $44.62 | $1.3M |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,005 | 30 | $0.09 | $268 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,460 | 32 | $0.67 | $1,646 |
| 99214 Office E&M - Established | Office | 900 | 353 | $107.45 | $97K |
| 96375 Injection Administration | Office | 529 | 37 | $14.64 | $7,745 |
| 96413 Chemotherapy Administration | Office | 449 | 52 | $125.22 | $56K |
| 96372 Injection Administration | Office | 391 | 62 | $12.75 | $4,986 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 261 | 137 | $14.54 | $3,796 |
| 99213 Office E&M - Established | Office | 207 | 117 | $76.49 | $16K |
| 96402 Chemotherapy Administration | Office | 172 | 17 | $32.82 | $5,645 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 139 | 13 | $0.90 | $124 |
| 96417 Chemotherapy Administration | Office | 131 | 22 | $62.37 | $8,170 |
| 96365 Intravenous Infusion, Hydration | Office | 128 | 49 | $58.47 | $7,484 |
By year: 2022 $4.6M for 275,870 services; 2023 $3.8M for 259,215 services; 2024 $4.2M for 251,351 services.
Medicare prescription drug claims, 2024
In 2024, the drug Igor Medic prescribed most often to Medicare patients was Anastrozole, with 157 prescriptions and refills. In total Igor Medic wrote 1,612 Medicare prescriptions that cost $6.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 157 | 277 | 29 | $1,805 |
| Xtandi Enzalutamide | 87 | 87 | 13 | $1.2M |
| Levothyroxine Sodium Generic | 83 | 112 | 14 | $510 |
| Dexamethasone Generic | 73 | 74 | 11 | $803 |
| Oxycodone Hcl Generic | 73 | 73 | 23 | $1,812 |
| Revlimid Lenalidomide | 71 | 71 | Under 11 | $1.2M |
| Ondansetron Hcl Generic | 63 | 63 | 35 | $1,635 |
| Exemestane Generic | 55 | 77 | Under 11 | $8,458 |
| Tamoxifen Citrate Generic | 54 | 104 | 12 | $1,441 |
| Acyclovir Generic | 50 | 78 | Under 11 | $612 |
| Prednisone Generic | 45 | 53 | 14 | $133 |
| Pantoprazole Sodium Generic | 34 | 36 | Under 11 | $159 |
| Verzenio Abemaciclib | 34 | 34 | Under 11 | $511K |
| Letrozole Generic | 34 | 45 | Under 11 | $497 |
| Ibrance Palbociclib | 30 | 30 | Under 11 | $473K |
Brand drugs: 457 claims; generic drugs: 1,155 claims; opioid claims: 145.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Igor Medic $3,052 ($3,052 in general payments such as food, travel and fees) from 47 companies. The largest payer was Novartis Pharmaceuticals Corporation with $252.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 11 | $252 |
| Celgene Corporation BMY | 13 | $234 |
| Pfizer Inc. PFE | 10 | $209 |
| GlaxoSmithKline, LLC. GSK | 7 | $149 |
| Genentech USA, Inc. ROG.SW | 5 | $128 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $124 |
| Genzyme Corporation SNY | 4 | $116 |
| Merck Sharp & Dohme LLC MRK | 4 | $115 |
| Karyopharm Therapeutics Inc. KPTI | 3 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $100 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.